BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.…
BBOT Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
BridgeBio Oncology Therapeutics (NASDAQ: BBOT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 84 employees.
The shares were at 1.810 USD on 20 November 2026, down 85.1% over 52 weeks. Its 52-week range is 1.785 USD to 14.87 USD: the price is 87.8% below the high and 1.4% above the low.
At a market capitalisation of 145.25M USD, it trades at 3.4 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 90% for BBOT.
BridgeBio Oncology Therapeutics reports return on equity of -32.6% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 191.49M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 4 March 2027.